Last reviewed · How we verify
NCT07260812
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 1 trial testing KSV01 Injection in Non-Hodgkin Lymphoma in 18 participants. Currently enrolling.
31 December 2028
Quick facts
| Lead sponsor | TCRx Therapeutics Co.Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 1 September 2025 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- KSV01 Injection — full drug profile →
Conditions studied
- Non-Hodgkin Lymphoma — all drugs for Non-Hodgkin Lymphoma →
- Diffuse Large B Cell Lymphoma (DLBCL) — all drugs for Diffuse Large B Cell Lymphoma (DLBCL) →
Sponsor
TCRx Therapeutics Co.Ltd — full company profile →
Who can join
Adults 18 to 65, any sex, with Non-Hodgkin Lymphoma or Diffuse Large B Cell Lymphoma (DLBCL). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single center, single arm, open-label, dose escalation, phase 1 study to evaluate the safety, tolerability and preliminary efficacy of KSV01 Injection for patients with diffuse large B-cell lymphoma.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07260812
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
- NCT07284927 — Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies · Phase 1 · recruiting
- NCT06176690 — Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas · Phase 1 · recruiting
- NCT06915246 — A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma · Phase 2 · recruiting
- NCT06418204 — Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics · recruiting
Other TCRx Therapeutics Co.Ltd trials
Trials by the same sponsor.
- NCT07275853 — Personalized KXV01 Lentinvivo (TCR) Injection as the Therapy for Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT07196579 — Personalized KXV01 TCR Lentinvivo Injection as the Therapy for Advanced Solid Tumors · Phase 1 · not yet recruiting
- NCT05811975 — KSX01-TCRT Injection Project in Solid Tumors · EARLY_PHASE1 · recruiting
- NCT05580796 — KSH01-R02-101 Solid Tumors · EARLY_PHASE1 · recruiting
- NCT05539833 — KSH01-TCRT Solid Tumors · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07260812 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by TCRx Therapeutics Co.Ltd
- Last refreshed: 13 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07260812.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing